°øÁö : µµÄìÁõ±Ç°Å·¡¼Ò JASDAQ ½ºÅÄ´Ùµå ½ÃÀå ½Å±Ô »óÀå °ü·Ã ¾È³»

Global Information
ȸ»ç¼Ò°³ | ¹®ÀÇ | ºñ±³¸®½ºÆ®

COVID-19 : ¹é½Å/Ä¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎ ¹× Áø´Ü Ãֽе¿Çâ - NewsLetter

BIS Research on COVID-19: An Indication Toward Solutions (Monthly Snapshot Report)

¸®¼­Ä¡»ç BIS Research Inc.
¹ßÇàÁ¤º¸ 12 ȸ/³â »óǰ ÄÚµå 953755
ÆäÀÌÁö Á¤º¸ ¿µ¹®
°¡°Ý
US $ 1,000 £Ü 1,130,000 PDF (Single User License)
US $ 1,500 £Ü 1,695,000 PDF (Corporate License)


COVID-19 : ¹é½Å/Ä¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎ ¹× Áø´Ü Ãֽе¿Çâ - NewsLetter BIS Research on COVID-19: An Indication Toward Solutions (Monthly Snapshot Report)
¹ßÇàÁ¤º¸ : 12 ȸ/³â ÆäÀÌÁö Á¤º¸ : ¿µ¹®

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹®¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹®¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

º» NewsLetter´Â COVID-19ÀÇ Áø´Ü, Ä¡·á, ¹é½Å °³¹ß¿¡ °üÇÑ End-to-EndÀÇ ½Ã±âÀûÀýÇÑ ¸®ºä¿Í ÃֽŠÁ¤º¸¸¦ ¸Å¿ù ÀüÇØµå¸³´Ï´Ù.

º» NewsLetterÀÇ Á¦°ø ³»¿ë

  • ¹é½Å°ú Ä¡·á¹ý °³¹ß °úÁ¤ÀÇ ºê·¹ÀÌÅ©½º·ç
  • COVID-19°¡ ¼¼°èÀÇ ºñÁö´Ï½º ½Ã³ª¸®¿À¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ °üÇÑ ½Å·Ú¼º ³ôÀº Á¤º¸
  • COVID-19ÀÇ ¹é½ÅÀ̳ª Ä¡·áÁ¦¸¦ °³¹ßÇϰí ÀÖ´Â ÁÖ¿ä ±â¾÷ Á¤º¸

º» NewsLetterÀÇ ÀÌÁ¡

  • COVID-19¿¡ °üÇÑ ÃֽŠÁ¤º¸¸¦ ¸Å¿ù ÀÔ¼öÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • BIS Research º¸°í¼­¿¡ °ÔÀçµÈ 100°³ ÀÌ»óÀÇ ÀÇ·á °ü·Ã º¸°í¼­ ÁÖ¿ä ¿ä¾à°ú ±â¾÷ °³¿ä¿¡ ¾×¼¼½º ÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • BIS Research°¡ ¹ßÇàÇÏ´Â º¸°í¼­¸¦ 20% ÇÒÀÎ ÇýÅÃÀ¸·Î ±¸ÀÔÇÒ ¼ö ÀÖ½À´Ï´Ù.
KSM 20.08.27

The report snapshot covers end-to-end timely review and updates for your business in the times of COVID-19, covering diagnostics, treatments, and vaccine development.

Combat the Pandemic's Impact on Your Business and Growth

BIS COVID - 19 Monthly Snapshot:

  • Available through monthly subscription
  • 1st week of every month
  • Insights to stay updated during the pandemic.

The single, monthly edition of our report snapshot covers:

  • breakthrough in the course of development of vaccines and treatment options during the pandemic
  • credible source of information related to impact of the COVID-19 on the global business scenario and relevant reports offered by BIS Research
  • key players developing vaccine and drug for COVID-19

Key Benefits

  • Stock prices of many pharma companies has risen by 20%-30% in the April 2020 as compared to Q3 FY20 period.
  • Operation Warp Speed (OWS) launched by The U.S. government for vaccine development
  • 116% Growth (Highest) Expected in AI-Enabled Solutions for Analysis of CT Images
  • 83.54% Growth (Highest) Expected in Europe in AIEnabled Medical Imaging Solutions Market Revenue in FY2020
Back to Top
ÀüÈ­ ¹®ÀÇ
F A Q